
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
Author(s) -
Cindy Neuzillet,
Olivia Hentic,
Benoı̂t Rousseau,
Vinciane Rebours,
Léïla Bengrine-Lefèvre,
Franck Bonnetain,
Philippe Lévy,
Éric Raymond,
Philippe Ruszniewski,
Christophe Louvet,
Pascal Hammel
Publication year - 2012
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v18.i33.4533
Subject(s) - irinotecan , folfiri , gemcitabine , medicine , regimen , gastroenterology , fluorouracil , chemotherapy , adenocarcinoma , oncology , surgery , colorectal cancer , cancer
To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts.